Skip to main navigation Skip to search Skip to main content

Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate: A nationwide cohort study in Denmark

  • Elisabeth Framke
  • , Finn Sellebjerg
  • , Matthias Kant
  • , Morten Stilund
  • , Henrik Boye Jensen
  • , Zsolt Illes
  • , Nasrin Asgari
  • , Tobias Sejbaek
  • , Lena Christina Roug
  • , Michael Broksgaard Jensen
  • , Jakob Schäfer
  • , Peter Vestergaard Rasmussen
  • , Jeppe Romme Christensen
  • , Arkadiusz Weglewski
  • , Sivagini Prakash
  • , Melinda Magyari
  • , Alex Heick
  • , Ana Isabel Figueira Jensen
  • , Arkadiusz Weglewski
  • , Ásta Milthers
  • Camilla Mærsk-Møller, Caroline Winther Tørring, Claudia Christensen, Finn Sellebjerg, Georgi P. Sirakov, Helle Hvilsted Nielsen, Henrik Boye Jensen, Henrik Kahr Mathiesen, Homayoun Roshanisefat, Inga Urbonaviciute, Ismael Barzinji, Jakob Schäfer, Jeppe Romme Christensen, Jette Lautrup Battistini, Julie Richter Hansen, Karen Ingrid Schreiber, Kristina Bacher Svendsen, Lars Kristian Storr, Lena Christina Roug, Luke Harper, Mai Bang Poulsen, Masoud Falah, Matthias Kant, Melinda Magyari, Michael Langemark, Michael Broksgaard Jensen, Monika Katarzyna Góra, Morten Blinkenberg, Morten Leif Munding Stilund, Nadia Mubder Issa, Nasrin Asgari, Per Soelberg Sørensen, Peter Vestergaard Rasmussen, Rikke Marie Jensen, Said Ashna, Siavash Derakhshan, Sivagini Prakash, Stephan Bramow, Tobias Sejbæk, Tsvetomir Asenov, Viktoria Papp Papp, Zsolt Laszlo Illés
  • University of Copenhagen
  • Gødstrup Hospital
  • University of Southern Denmark
  • Institute of Regional Health Research

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background: Teriflunomide has been associated with an increased risk of hypertension. Real-world studies including adequate control groups are lacking. We hypothesized that patients with multiple sclerosis (MS) treated with teriflunomide would be at higher risk of developing hypertension than those treated with dimethyl fumarate. Methods: We conducted a cohort study linking the Danish Multiple Sclerosis Registry with national health registries during a 10-year period. Teriflunomide (N = 2656) and dimethyl fumarate (N = 2237) exposure was defined by the first treatment record lasting ⩾ 3 months, at which time follow-up started. We included 4893 adult patients without hypertension at baseline. Hypertension was defined as an International Classification of Diseases 10th Revision code for hypertension and by dispensed prescription drugs identified by the respective Anatomical Therapeutic Chemical codes. We used multivariable-adjusted Cox regression. Results: We found 40.6 (teriflunomide) and 13.1 (dimethyl fumarate) hypertension events per 1000 person-years. Compared to dimethyl fumarate-treated patients, patients treated with teriflunomide had a higher risk of developing hypertension (adjusted hazard ratio = 2.80; 95% confidence interval = 2.19–3.56). The number needed to harm was 16 and 9 at 3 and 5 years of follow-up, respectively. Conclusion: We found an increased risk of hypertension in adult patients with MS treated with teriflunomide.

Original languageEnglish
Pages (from-to)36-43
Number of pages8
JournalMultiple Sclerosis Journal
Volume31
Issue number1
DOIs
StatePublished - Jan 2025

Keywords

  • Teriflunomide
  • dimethyl fumarate
  • hypertension
  • multiple sclerosis
  • safety

Fingerprint

Dive into the research topics of 'Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate: A nationwide cohort study in Denmark'. Together they form a unique fingerprint.

Cite this